VivoSeq
Neurology

Moderate to Severe Alzheimer's Disease

0

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Moderate to Severe Alzheimer's Disease is an early-stage landscape with 0 programs across 4 companies. The most active players are Eisai, Lundbeck, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

64/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eisai logo

Eisai

0 programs

PreclinicalLundbeck logo

Lundbeck

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalS

Samsung Pharmaceutical Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

14

clinical trials

Completed7 · 50%
Terminated4 · 29%
Unknown status2 · 14%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
Not yet recruiting·SSamsung Pharmaceutical Co., Ltd.·Phase 3·NCT05303701·750 enrolled
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
Completed·FForest Laboratories·Phase 3·NCT00322153·677 enrolled
The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
Completed·FForest Laboratories·Phase 3·NCT00090116·400 enrolled
Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
Completed·Eisai logoEisai·Phase 4·NCT02097056·171 enrolled
Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease
Completed·CCarnot Laboratories·Phase 4·NCT07417670·105 enrolled
An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease
Completed·FForest Laboratories·Phase 3·NCT00097916·34 enrolled
Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
Completed·Eisai logoEisai·Phase 3·NCT00566501·915 enrolled
Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
Completed·Eisai logoEisai·Phase 3·NCT00478205·1,467 enrolled
A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease
Terminated·MMedivation, Inc.·Phase 3·NCT00954590·89 enrolled
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
Terminated·Pfizer logoPfizer·Phase 3·NCT00912288·86 enrolled
Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease
Terminated·Lundbeck logoLundbeck·Phase 3·NCT00857233·297 enrolled
Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease
Terminated·Lundbeck logoLundbeck·Phase 3·NCT00857649·369 enrolled
Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease
Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 4·NCT05430867·150 enrolled
Donepezil and Memantine in Moderate to Severe Alzheimer's Disease
Unknown status·KKing's College London·Phase 4·NCT00866060·800 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)